Ark Therapeutics plans UK listing for up to $57 million
This article was originally published in Clinica
UK company Ark Therapeutics, which develops medical products and pharmaceuticals aimed at vascular disease and cancer, aims to raise £30-40 million ($43-57 million) through its flotation on the London Stock Exchange.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.